In Q3, a recovery in sales was visible, primarily driven by Spain and the Diafarm franchisee. Moreover, limited traveling amidst the pandemic boosted the bottom-line. However, given that the second wave of COVID-19 could hamper the recovery of the lynchpin drug, Bilastine, Q4 is expected to be soft, though the robust underlying demand for Hidroferol and immune booster drugs could provide some respite.
11 Nov 2020
Second wave of lockdowns could weigh on Q4
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Second wave of lockdowns could weigh on Q4
In Q3, a recovery in sales was visible, primarily driven by Spain and the Diafarm franchisee. Moreover, limited traveling amidst the pandemic boosted the bottom-line. However, given that the second wave of COVID-19 could hamper the recovery of the lynchpin drug, Bilastine, Q4 is expected to be soft, though the robust underlying demand for Hidroferol and immune booster drugs could provide some respite.